Clinical Trials Browser

Phase 1/2 × Colorectal Neoplasms × Cetuximab × Clear all

NCT07020221 2026-04-22

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase 1/2 Recruiting

CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT05358249 2026-04-14

KontRASt-03

Phase 1/2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07223047 2026-04-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07468071 2026-04-02

KontRASt-R

Phase 1/2 Not yet recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 1/2 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05200442 2026-03-30

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07397338 2026-03-30

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05039177 2026-03-25

HERKULES-3

Phase 1/2 Completed

Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07411599 2026-03-12

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT06412198 2026-03-06

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07259590 2025-12-02

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04017650 2025-11-20

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Phase 1/2 Active not recruiting

731 enrolled 2 FDA

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Phase 1/2 Recruiting

GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05775900 2025-09-03

Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT06024174 2025-07-22

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Phase 1/2 Terminated

5 enrolled 9 charts

GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04616196 2025-06-08

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Phase 1/2 Completed

25 enrolled 17 charts

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms

NCT04495621 2025-05-01

C-PRECISE-01

Phase 1/2 Completed

29 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT03428958 2025-04-23

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT00545545 2025-03-19

Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma

Phase 1/2 Completed

32 enrolled 23 charts

Gastrointestinal

Carcinoma, Recurrence, Colorectal Neoplasms

NCT03169777 2025-02-21

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT03563157 2024-12-11

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Phase 1/2 Terminated

2 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT02713373 2022-10-06

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Completed

45 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT04165031 2021-11-24

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Phase 1/2 Terminated

5 enrolled 9 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT01960023 2021-10-27

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02117466 2021-04-14

IMPACT-CRC

Phase 1/2 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT01075048 2021-04-08

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Phase 1/2 Completed

131 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT02953782 2021-03-01

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Phase 1/2 Completed

78 enrolled 27 charts

Gastrointestinal

Colorectal Neoplasms

NCT02318901 2019-10-21

PembroMab

Phase 1/2 Terminated

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT01252628 2018-05-16

Phase 1 and 2 Study of PX-866 and Cetuximab

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Squamous Cell, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Colorectal Neoplasms

NCT02278133 2017-10-09

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Phase 1/2 Completed

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00361244 2017-02-17

SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

Phase 1/2 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT01086267 2016-06-27

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01008475 2016-03-30

POSEIDON

Phase 1/2 Completed

232 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

NCT00594984 2015-11-04

Phase I/II Combination With Irinotecan- Erbitux

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00522665 2015-05-15

Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00778830 2015-05-14

APEC

Phase 1/2 Completed

289 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT00908024 2013-06-18

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

GastrointestinalHead & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT01166035 2010-07-20

TEXO

Phase 1/2 Unknown

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

NCT00422773 2009-02-27

Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms